![]() ![]() Se buscó sistemáticamente las GPC publicadas en los últimos 3 años en bases de datos, repositorios y organismos elaboradores. (Funded by Merck Sharp & Dohme TECOS number, NCT00790205.).Įmitir recomendaciones para el manejo de la diabetes en pacientes con falla cardiaca, contextualizadas al Hospital Nacional Daniel Alcides Carrión (HNDAC) del Callao, Perú. There were no significant between-group differences in rates of acute pancreatitis (P=0.07) or pancreatic cancer (P=0.32).Īmong patients with type 2 diabetes and established cardiovascular disease, adding sitagliptin to usual care did not appear to increase the risk of major adverse cardiovascular events, hospitalization for heart failure, or other adverse events. Rates of hospitalization for heart failure did not differ between the two groups (hazard ratio, 1.00 95% CI, 0.83 to 1.20 P=0.98). Sitagliptin was noninferior to placebo for the primary composite cardiovascular outcome (hazard ratio, 0.98 95% CI, 0.88 to 1.09 P<0.001). Overall, the primary outcome occurred in 839 patients in the sitagliptin group (11.4% 4.06 per 100 person-years) and 851 patients in the placebo group (11.6% 4.17 per 100 person-years). placebo, -0.29 percentage points 95% confidence interval, -0.32 to -0.27). ![]() The primary cardiovascular outcome was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina.ĭuring a median follow-up of 3.0 years, there was a small difference in glycated hemoglobin levels (least-squares mean difference for sitagliptin vs. ![]() To determine whether sitagliptin was noninferior to placebo, we used a relative risk of 1.3 as the marginal upper boundary. Open-label use of antihyperglycemic therapy was encouraged as required, aimed at reaching individually appropriate glycemic targets in all patients. In this randomized, double-blind study, we assigned 14,671 patients to add either sitagliptin or placebo to their existing therapy. Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |